Hgf-sf monoclonal antibody combinations

Abstract

The present invention provides a combination of anti-HGF/SF antibodies that specifically bind HGF/SF and inhibits HGF/SF activity. The present invention further provides a combination of anti-HGF/SF antibodies comprising three or more anti-HGF/SF antibodies selected from the group consisting of: antibody #1 produced from hybridoma 1C10-F1-A11, antibody #4 produced from hybridoma 8H2-F2-B10, antibody #5 produced from hybridoma 13B1-E4-E10, antibody #7 produced from hybridoma 15D7-B2, and antibody #10 produced from hybridoma 31D4-C9-D4. The invention also provides a method of treating cancer in a subject comprising administering to the subject a combination of anti-HGF/SF antibodies whereby the antibodies bind to a hepatocyte growth factor, whereby the binding of the antibodies to a hepatocyte growth factor results in an inhibition of hepatocyte growth factor binding to the hepatocyte growth factor receptor, whereby the inhibition of hepatocyte growth factor binding to receptor causes an inhibition of cancer growth, thereby treating the cancer.

1 . A combination of anti-HGF/SF antibodies that specifically binds HGF/SF and inhibits HGF/SF activity. 
   
   
       2 . A combination of anti-HGF/SF antibodies comprising three or more anti-HGF/SF antibodies selected from the group consisting of: antibody #1 produced from hybridoma 1C10-F1-A11, antibody #4 produced from hybridoma 8H2-F2-B 10, antibody #5 produced from hybridoma 13B1-E4-E10, antibody #7 produced from hybridoma 15D7-B2, and antibody #10 produced from hybridoma 31D4-C9-D4. 
   
   
       3 . The combination of  claim 2 , comprising antibody #1 produced from hybridoma 1C10-F1-A11, antibody #5 produced from hybridoma 13B1-E4-E10 and antibody #7 produced from hybridoma 15D7-B2. 
   
   
       4 . The combination of  claim 2 , comprising antibody #1 produced from hybridoma 1C10-F1-A11, antibody #4 produced from hybridoma 8H2-F2-B10 and antibody #7 produced from hybridoma 15D7-B2. 
   
   
       5 . The combination of  claim 2 , comprising antibody #1 produced from hybridoma 1C10-F1-A11, antibody #5 produced from hybridoma 13B1-E4-E10 and antibody #10 produced from hybridoma 31D4-C9-D4. 
   
   
       6 . The combination of  claim 2 , comprising antibody #1 produced from hybridoma 1-10-F1-A11, antibody #4 produced from hybridoma 8H2-F2-B10 and antibody #10 produced from hybridoma 31D4-C9-D4. 
   
   
       7 . Anti-HGF/SF antibody A.1 produced from hybridoma 1C10-F1-A11. 
   
   
       8 . A composition comprising the antibody of  claim 7 . 
   
   
       9 . Anti-HGF/SF antibody A.4 produced from hybridoma 8H2-F2-B10. 
   
   
       10 . A composition comprising the antibody of  claim 9 . 
   
   
       11 . Anti-HGF/SF antibody A.5 produced from hybridoma 13B1-E4-E10. 
   
   
       12 . A composition comprising the antibody of  claim 11 . 
   
   
       13 . Anti-HGF/SF antibody A.7 produced from hybridoma 15D7-B2. 
   
   
       14 . A composition comprising the antibody of  claim 13 . 
   
   
       15 . Anti-HGF/SF antibody A.10 produced from hybridoma 31D4-C9-D4. 
   
   
       16 . A composition comprising the antibody of  claim 15 . 
   
   
       17 . A method of treating cancer in a subject comprising administering to the subject the antibodies of  claims 1 ,  2 ,  3 ,  4 ,  5  or  6 , whereby the antibodies bind to a hepatocyte growth factor, whereby the binding of the antibodies to a hepatocyte growth factor results in an inhibition of hepatocyte growth factor binding to the hepatocyte growth factor receptor, whereby the inhibition of hepatocyte growth factor binding to receptor causes an inhibition of cancer growth, thereby treating the cancer. 
   
   
       18 . A method of screening a subject for the presence of a developmental disorder comprising:
 a) contacting a tissue sample from the subject with the antibodies of  claims 1 ,  2 ,  3 ,  4 ,  5  or  6 ;   b) detecting the binding of the antibodies with an antigen in the tissue sample, whereby a reduction in binding of antigen to the antibodies in the tissue sample relative to the binding of antigen from a control tissue sample to the antibodies indicates a decreased amount of hepatocyte growth factor in the sample; whereby the reduction in the amount of hepatocyte growth factor indicates a developmental disorder is present in the patient, thereby screening the subject for the presence of a developmental disorder   
   
   
       19 . The method of  claim 18  wherein the developmental disorder comprises those conditions resulting from an abnormal epithelial-mesenchymal cell conversion. 
   
   
       20 . A method of determining the progression of cancer comprising:
 a) contacting a tissue sample from a patient having a cancer with the antibody of  claims 1 ,  2 ,  3 ,  4 ,  5 , or  6 ;   b) detecting the binding of the antibodies with an antigen;   c) measuring the amount of antigen in the sample; and   d) correlating the binding of the antibodies with the antigen with a clinically defined stage of cancer development, thereby determining the progression of cancer in the patient.   
   
   
       21 . A method of detecting the presence of cancer in a patient comprising:
 a) contacting a tissue sample from the subject with the antibodies of  claims 1 ,  2 ,  3 ,  4 ,  5 , or  6 .   b) detecting the binding of the antibodies with an antigen in the sample, whereby an increased binding of antigen to the antibodies relative to the binding of antigen from a control tissue sample to the antibodies indicates an increased amount of hepatocyte growth factor in the sample, whereby the increased amount of hepatocyte growth factor indicates the presence of cancerous tissue in the sample, thereby detecting the presence of cancer in the patient.